CEA-targeted CAR-T cells
Phase 2Cell therapy
CEA-targeted CAR-T cells is one of 110 biologic programs targeting Colorectal Cancer. It is currently in Phase 2.
3
Indications
6
Total Trials
5
Active Trials
109
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
286 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Paraplatin
AAvyxa
Phase 2
Tecentriq
RochePhase 2
Taxotere
AAvyxa
Phase 2
Yervoy
Bristol-Myers SquibbPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Braftovi
PfizerPhase 2
Erbitux
IImclone
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors2 trials
Advanced Malignant Solid Tumors2 trials
Colorectal Cancer1 trial
CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07247396·12 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CEA-targeted CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details